RHO.BE : Summary for ROCHE HLDG AG INH. SF 1 - Yahoo Finance

U.S. Markets close in 4 hrs 19 mins

ROCHE HLDG AG INH. SF 1 (RHO.BE)


Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
240.83+2.98 (+1.25%)
As of 5:15PM CEST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close237.85
Open237.57
Bid239.95 x 79100
Ask241.10 x 10000
Day's Range237.57 - 240.83
52 Week Range205.07 - 247.28
Volume61
Avg. Volume35
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis
    Zacks18 hours ago

    Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis

    Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.

  • Reutersyesterday

    UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay

    The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).

  • Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA
    Zacks6 days ago

    Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

    Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.